MY MAN rates Hana Biosciences (Nasdaq: HNAB) a buy, my man.

Click on image above for resolution, my man

MY MAN feels bad about this one because HNAB was hanging around twenty cent fo' a long time, damn, my man. MY MAN got 100 shares of this shortie a long time ago and forgot all about it, my man.

But Sheeeeeeeeeeeeeeeeeeeeeeit (click here) it's climbing up and MY MAN thinks HNAB has got the potential to go a lot higher, my man.

This here be their site, my man

Now look here now:

NEW YORK, July 21 (Reuters) - Gambling on volatile small-cap biotechnology companies can be gut wrenching even in the best of times, but wild stock jumps based on positive clinical data may tempt investors to give them a second look with the hope of catching that really big payoff.

Human Genome Sciences Inc this week provided the latest golden carrot that investors may follow back into the sector.

But John McCamant, editor of the Medical Technology Stock Letter, is preaching diversification by investing in companies of varying sizes and with different technologies while staying away from companies with cash problems.

"You need to diversify because some of these are still going to blow up. If Human Genome didn't win, it was probably going to go down 50-plus percent," McCamant said.

McCamant also suggested keeping an eye on any company that lands former top Genentech talent after that company's purchase by Roche. He noted that Human Genome's current head of research and development came from Genentech.

He mentioned MicroMet Inc, Amicus Therapeutics Inc, Hana Biosciences Inc and Allos Therapeutics Inc as potential small biotech basket options. Becker said he does not have any long or short positions in the companies he discussed.


Here's the whole damn thing, my man.